|Assessment Status||Rapid Review Complete|
|Indication||In combination with chlorambucil or bendamustine for the treatment of patients with chronic lymphocytic leukaemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy.|
|Rapid review commissioned||13/10/2014|
|Rapid review completed||18/12/2014|
|Rapid review outcome||Full Pharmacoeconomic Assessment Recommended at the submitted price.|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.